Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Apr;71(4):808–813. doi: 10.1038/bjc.1995.156

Oncogene-linked in situ immunotherapy of pre-B lymphoma arising in E mu/ret transgenic mice.

M Ichihara 1, T Iwamoto 1, K Isobe 1, M Takahashi 1, A Nakayama 1, M Pu 1, Y Dai 1, A Parashar 1, K Ohkus 1, M Kato 1, et al.
PMCID: PMC2033753  PMID: 7710948

Abstract

We attempted to induce anti-tumour immunity for rejecting pre-B lymphoma derived from E mu/ret transgenic mice (TGM). We established pre-B-lymphoma cell lines of C57BL/6 x Balb/c background (H-2b/d) into which H-2k alloantigen and C3H background were introduced (retL1-6 and retL6-6), and we inoculated BCF1 mice with these immunising tumour cells. After these tumours were rejected by alloantigen (H-2k/C3H background)-specific effector cells, the mice were challenged with the pre-B-lymphoma cell line derived from the original E mu/ret TGM (ret0-2). All non-immunised control mice died within 80 days, whereas half the immunised mice survived for over 300 days. The immunity was also effective against primary pre-B-lymphoma cells from E mu/ret TGM and the ret-driven melanoma cell line (MEL-ret), but not against the pre-B-lymphoma cell line from E mu/myc TGM. This immunity was at least in part mediated by cell-mediated cytotoxicity that was specific to the ret oncogene product or ret-regulated antigen. Next we immunised E mu/ret TGM by inoculating them with retL6-6 cells once every 2 weeks beginning at the age of 1 month. Interestingly, this immunisation enabled the TGM to survive longer than the non-immunised control group (P < 0.05). Moreover, 2 of 11 transgenic mice receiving such immunisation were free from both macroscopic and microscopic tumours at the time when all of the 12 non-immunised control TGM had died from their tumour. This provides a new model for oncogene-linked immunotherapy research.

Full text

PDF
808

Images in this article

811Figure 4
on p.811

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ando K. I., Isobe K. I., Hasegawa T., Iwamoto T., Ding R. N., Rahman J., Muro Y., Yoshida T., Nagase F., Kawashima K. Genetic and stimulator cell requirements for generation and activation of minor histocompatibility antigen-specific memory cytotoxic T-lymphocyte precursors. Immunology. 1988 Aug;64(4):661–667. [PMC free article] [PubMed] [Google Scholar]
  2. Brichard V., Van Pel A., Wölfel T., Wölfel C., De Plaen E., Lethé B., Coulie P., Boon T. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med. 1993 Aug 1;178(2):489–495. doi: 10.1084/jem.178.2.489. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chen L. P., Thomas E. K., Hu S. L., Hellström I., Hellström K. E. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):110–114. doi: 10.1073/pnas.88.1.110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dyson N., Buchkovich K., Whyte P., Harlow E. The cellular 107K protein that binds to adenovirus E1A also associates with the large T antigens of SV40 and JC virus. Cell. 1989 Jul 28;58(2):249–255. doi: 10.1016/0092-8674(89)90839-8. [DOI] [PubMed] [Google Scholar]
  5. Faas S. J., Pan S., Pinkert C. A., Brinster R. L., Knowles B. B. Simian virus 40 (SV40)-transgenic mice that develop tumors are specifically tolerant to SV40 T antigen. J Exp Med. 1987 Feb 1;165(2):417–427. doi: 10.1084/jem.165.2.417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Feramisco J. R., Clark R., Wong G., Arnheim N., Milley R., McCormick F. Transient reversion of ras oncogene-induced cell transformation by antibodies specific for amino acid 12 of ras protein. Nature. 1985 Apr 18;314(6012):639–642. doi: 10.1038/314639a0. [DOI] [PubMed] [Google Scholar]
  7. Gannon J. V., Greaves R., Iggo R., Lane D. P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 1990 May;9(5):1595–1602. doi: 10.1002/j.1460-2075.1990.tb08279.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hellström K. E., Hellström I. Oncogene-associated tumor antigens as targets for immunotherapy. FASEB J. 1989 Apr;3(6):1715–1722. doi: 10.1096/fasebj.3.6.2649402. [DOI] [PubMed] [Google Scholar]
  9. Humphrey P. A., Wong A. J., Vogelstein B., Zalutsky M. R., Fuller G. N., Archer G. E., Friedman H. S., Kwatra M. M., Bigner S. H., Bigner D. D. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A. 1990 Jun;87(11):4207–4211. doi: 10.1073/pnas.87.11.4207. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Isobe K., Hasegawa Y., Iwamoto T., Hasegawa T., Kawashima K., Ding L. N., Nakashima I. Induction of antitumor immunity in mice by allo-major histocompatibility complex class I gene transfectant with strong antigen expression. J Natl Cancer Inst. 1989 Dec 6;81(23):1823–1828. doi: 10.1093/jnci/81.23.1823. [DOI] [PubMed] [Google Scholar]
  11. Iwamoto T., Pu M., Ito M., Takahashi M., Isobe K., Nagase F., Kawashima K., Ichihara M., Nakashima I. Preferential development of pre-B lymphomas with drastically down-regulated N-myc in the E mu-ret transgenic mice. Eur J Immunol. 1991 Aug;21(8):1809–1814. doi: 10.1002/eji.1830210805. [DOI] [PubMed] [Google Scholar]
  12. Iwamoto T., Takahashi M., Ito M., Hamatani K., Ohbayashi M., Wajjwalku W., Isobe K., Nakashima I. Aberrant melanogenesis and melanocytic tumour development in transgenic mice that carry a metallothionein/ret fusion gene. EMBO J. 1991 Nov;10(11):3167–3175. doi: 10.1002/j.1460-2075.1991.tb04878.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Iwamoto T., Taniguchi M., Asai N., Ohkusu K., Nakashima I., Takahashi M. cDNA cloning of mouse ret proto-oncogene and its sequence similarity to the cadherin superfamily. Oncogene. 1993 Apr;8(4):1087–1091. [PubMed] [Google Scholar]
  14. Jung S., Schluesener H. J. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med. 1991 Jan 1;173(1):273–276. doi: 10.1084/jem.173.1.273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Klein G. Tumor antigens. Annu Rev Microbiol. 1966;20:223–252. doi: 10.1146/annurev.mi.20.100166.001255. [DOI] [PubMed] [Google Scholar]
  16. Linsk R., Vogel J., Stauss H., Forman J., Goodenow R. S. Structure and function of three novel MHC class I antigens derived from a C3H ultraviolet-induced fibrosarcoma. J Exp Med. 1986 Sep 1;164(3):794–813. doi: 10.1084/jem.164.3.794. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lurquin C., Van Pel A., Mariamé B., De Plaen E., Szikora J. P., Janssens C., Reddehase M. J., Lejeune J., Boon T. Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells. Cell. 1989 Jul 28;58(2):293–303. doi: 10.1016/0092-8674(89)90844-1. [DOI] [PubMed] [Google Scholar]
  18. Maki R. G., Old L. J., Srivastava P. K. Human homologue of murine tumor rejection antigen gp96: 5'-regulatory and coding regions and relationship to stress-induced proteins. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5658–5662. doi: 10.1073/pnas.87.15.5658. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mulligan L. M., Kwok J. B., Healey C. S., Elsdon M. J., Eng C., Gardner E., Love D. R., Mole S. E., Moore J. K., Papi L. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature. 1993 Jun 3;363(6428):458–460. doi: 10.1038/363458a0. [DOI] [PubMed] [Google Scholar]
  20. Old L. J., Stockert E. Immunogenetics of cell surface antigens of mouse leukemia. Annu Rev Genet. 1977;11:127–160. doi: 10.1146/annurev.ge.11.120177.001015. [DOI] [PubMed] [Google Scholar]
  21. Peace D. J., Chen W., Nelson H., Cheever M. A. T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J Immunol. 1991 Mar 15;146(6):2059–2065. [PubMed] [Google Scholar]
  22. Plautz G. E., Yang Z. Y., Wu B. Y., Gao X., Huang L., Nabel G. J. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci U S A. 1993 May 15;90(10):4645–4649. doi: 10.1073/pnas.90.10.4645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pullano T. G., Sinn E., Carney W. P. Characterization of monoclonal antibody R256, specific for activated ras p21 with arginine at 12, and analysis of breast carcinoma of v-Harvey-ras transgenic mouse. Oncogene. 1989 Aug;4(8):1003–1008. [PubMed] [Google Scholar]
  24. Schreiber H., Ward P. L., Rowley D. A., Stauss H. J. Unique tumor-specific antigens. Annu Rev Immunol. 1988;6:465–483. doi: 10.1146/annurev.iy.06.040188.002341. [DOI] [PubMed] [Google Scholar]
  25. Skipper J., Stauss H. J. Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein. J Exp Med. 1993 May 1;177(5):1493–1498. doi: 10.1084/jem.177.5.1493. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Srivastava P. K., DeLeo A. B., Old L. J. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A. 1986 May;83(10):3407–3411. doi: 10.1073/pnas.83.10.3407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Stauss H. J., Van Waes C., Fink M. A., Starr B., Schreiber H. Identification of a unique tumor antigen as rejection antigen by molecular cloning and gene transfer. J Exp Med. 1986 Nov 1;164(5):1516–1530. doi: 10.1084/jem.164.5.1516. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Takahashi M., Ritz J., Cooper G. M. Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985 Sep;42(2):581–588. doi: 10.1016/0092-8674(85)90115-1. [DOI] [PubMed] [Google Scholar]
  29. Taniguchi M., Iwamoto T., Nakashima I., Nakayama A., Ohbayashi M., Matsuyama M., Takahashi M. Establishment and characterization of a malignant melanocytic tumor cell line expressing the ret oncogene. Oncogene. 1992 Aug;7(8):1491–1496. [PubMed] [Google Scholar]
  30. Ullrich S. J., Robinson E. A., Law L. W., Willingham M., Appella E. A mouse tumor-specific transplantation antigen is a heat shock-related protein. Proc Natl Acad Sci U S A. 1986 May;83(10):3121–3125. doi: 10.1073/pnas.83.10.3121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Urban J. L., Schreiber H. Tumor antigens. Annu Rev Immunol. 1992;10:617–644. doi: 10.1146/annurev.iy.10.040192.003153. [DOI] [PubMed] [Google Scholar]
  32. Yanuck M., Carbone D. P., Pendleton C. D., Tsukui T., Winter S. F., Minna J. D., Berzofsky J. A. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res. 1993 Jul 15;53(14):3257–3261. [PubMed] [Google Scholar]
  33. Yukawa K., Kikutani H., Inomoto T., Uehira M., Bin S. H., Akagi K., Yamamura K., Kishimoto T. Strain dependency of B and T lymphoma development in immunoglobulin heavy chain enhancer (E mu)-myc transgenic mice. J Exp Med. 1989 Sep 1;170(3):711–726. doi: 10.1084/jem.170.3.711. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES